Research programme: cardiovascular disorders therapy - DURECT
Alternative Names: Cardiovascular disorders therapy research programme - DURECTLatest Information Update: 28 Dec 2017
At a glance
- Originator DURECT Corporation
- Class Growth factors
- Mechanism of Action Angiogenesis inducing agents; Growth factor receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 28 Dec 2017 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA (Parenteral)
- 18 Dec 2015 Preclinical development for Cardiovascular disorders is ongoing in USA
- 07 Dec 2004 Preclinical trials in Cardiovascular disorders in Netherlands (Parenteral)